Skip to main
OTLK

OTLK Stock Forecast & Price Target

OTLK Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 0%
Hold 67%
Sell 0%
Strong Sell 0%

Bulls say

Outlook Therapeutics Inc is experiencing a positive trajectory following the commercial launch of its product, Lytenava, which generated $1.4 million in revenue during its first month of sales in Germany and the UK, indicating strong initial market acceptance. The company has reported an increase in both the number of accounts ordering Lytenava and the breadth of prescribing physicians, suggesting a growing adoption of the treatment in the early stages of FY2026. Additionally, positive data from the NORSE EIGHT trial supporting ONS-5010’s noninferiority to ranibizumab further enhances the company's standing and potential for significant revenue growth in the ophthalmic market.

Bears say

Outlook Therapeutics Inc faces significant challenges that contribute to a negative outlook on its stock, primarily stemming from its reliance on ONS-5010, which has seen diminishing commercial prospects due to a rapid decline in pricing within the theranibizumab market. The company's recent financial performance reflects a notable reduction in R&D expenses, yet this may suggest insufficient investment in advancing its sole active development program, increasing the risk of clinical trial failures and potential regulatory hurdles. Furthermore, negative results from the NORSE EIGHT clinical study and regulatory setbacks such as the complete response letter for Lytenava signal serious concerns regarding the viability of the product pipeline, alongside potential need for additional financing that could dilute existing shareholder value.

OTLK has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 0% recommend Buy, 67% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Outlook Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Outlook Therapeutics Inc (OTLK) Forecast

Analysts have given OTLK a Buy based on their latest research and market trends.

According to 3 analysts, OTLK has a Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $3.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $3.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Outlook Therapeutics Inc (OTLK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.